Drug-release type gel for treating fundus macular degeneration and preparation method thereof

Abstract

The invention discloses drug-release type gel for treating fundus macular degeneration and a preparation method thereof. The drug-release type gel comprises an anti-angiogenesis drug, an inducing compound and gel and is characterized in that the inducing compound is used for increasing the permeation of the drug, and the gel attaches to the cornea during use and serves as the carrier of the drug;the anti-angiogenesis drug is selected from Lucentis or Compaq; the inducing compound is selected from optional one of dexamethasone, prednisone and cortisone or the combination of two of dexamethasone, prednisone and cortisone; the gel serving as the drug carrier is prepared by preparing a solution containing polydopamine and methacrylate gelatin, adding crosslinking agent N,N-methylene bisacrylamide and initiator potassium peroxydisulfate into the solution, and performing fixed-die forming to obtain the gel which does not contain the drug. The drug-release type gel has the advantages that non-invasive drug delivery is adopted, sustained drug release is achieved after the gel attaches to the cornea, and the anti-VEGF drug is allowed to act on the vitreous body by utilizing the permeability of the inducing compound.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a medicine slow-release gel, in particular to a medicine-release gel for treating fundus and macula and a preparation method thereof. Background technique [0002] Age-related macular degeneration, also known as age-related macular degeneration (AMD). Exudation, degeneration, or subretinal hemorrhage in the macula of the affected eye. The disease mostly occurs in middle-aged and elderly people, and its prevalence is positively correlated with age. It is currently the main cause of blindness in people over 50 years old. With the aging of the Chinese population, the disease has a clear upward trend. In terms of clinical manifestations, AMD is divided into dry (atrophic) AMD and wet AMD (neovascular). Among them, dry AMD does not cause serious visual impairment in the early stage of the lesion, but once neovascularization occurs in wet AMD, there will be obvious weakening of visio...

AI Technical Summary

Problems solved by technology

The two drugs have the following disadvantages in the way of administration: 1. Need to puncture the eyeball to achieve intravitreal injection, which is difficult to operate and requires very high qualification requirements for surgeons; 2. The price of drugs and surgical fees are high, and patients will Pain during treatment; 3. It is easy to cause adverse reactions such as bleeding at the injection site, conjunctival hyperemia, and increased intraocular pressure; 4. There are risks of infection, iritis, retinal tear, etc.